Company intelligence / Profile preview

Biotecnomed

Catanzaro, Calabria, Italybiotecnomed.it ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Biotecnomed has completed experimentation and method validation on a cancer immunomodulator peptide with improved tumor penetration, clearance, flexibility for combination therapies, and low production cost. They have also validated a rapid miRNA-based screening test ("BREATHLESS") for lung injury assessment in subjects exposed to environmental pollutants.[5] The company is primarily focused on R&D services rather than direct clinical development.

Therapeutic areas: Metabolic DisordersPulmonologyOncology
Modalities: PeptidesSmall moleculeRNA therapy
Industry: Drug Discovery Services

Partnerships

Works closely with regional universities, Italy’s national research council, private research bodies, small-to-large enterprises in Calabria region. No major global pharma partnerships disclosed.

Beyond the preview

Go deeper on Biotecnomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotecnomed.

Explore the full profile